Dopamine agonists
Pramipexole, ropinirole, rotigotine and apomorphine — efficacy, dyskinesia risk and impulse-control side effects.
State of the art
No update yet for Dopamine agonists. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Addressing Care Partner Burden from the Underrecognition of Iatrogenic Sexual Behavior Changes in Parkinson's Disease
The paper highlights that dopamine agonist-induced hypersexuality — an impulse-control side effect affecting an estimated 1 in 7 people on these drugs — is frequently unrecognised as medication-caused by the care partner, compounding relationship distress and delaying the medication adjustment (dose reduction or switch) that would typically resolve it. The authors frame under-disclosure of this risk at prescribing as a specific, preventable driver of care-partner harm.